Ind-Swift Laboratories Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/197zs14w1ewyiywjo9rwy50l.pdf

Key Takeaways


CDMO Commercialization & Customer Concentration

Aggarwal: "We are well prepared and we are committing to our customers as and when we'll be ready for commercialization. So, the day we committed for Viatris we delivered."

Product Launches & Pipeline

Aggarwal: "We don't want to spend a single penny in R&D before we sign off any agreement with our customers. And in most of the cases, all the development cost which we bear is borne by our customer only."

Margin Profile & Sustainability

Aggarwal: "Yes, 18% is fully sustainable and we plan if the sales we are able to increase quarter-on-quarter they might go up to 21 to 22%."

Export Mix & Revenue Composition


Capacity, Capex & Infrastructure


Synthimed Stake & API Divestment Legacy

Aggarwal: "The decision was very clear that API business is doing good, we should exit that API business, get value, make the group debt-free."

Guidance & Commitments

CommitmentSpecificsTimeline
CDMO incremental revenue₹200–220 crore from CDMO partnershipsFY27
Viatris year-one sales₹100–130 crore from Ibuprofen and Clarithromycin granulesYear one (FY27)
Full CDMO revenue from Viatris project₹200 croreBy FY29
Viatris volume growthQ2 volumes double versus Q1Q2 FY27
Arrotex Macrogol pushMajor push on Macrogol moleculeQ2 FY27
Ibuprofen and Clarithromycin granules progressProgress from these moleculesQ3 and Q4 FY27
EBITDA margin increaseIncrease from 18%Q3 FY27 (internal plan: Q2)
FY27 revenue₹900 croreFY27
FY27 export sales₹750 crore, ~45% via CDMOFY27
Dossier count2,500 dossiersQ4 FY27
FY29 revenue₹1,200 crore, including ₹600–650 crore CDMOFY29
FY30 visionMinimum ₹1,500 crore revenue, ₹200 crore+ net profitFY30
Cash deployment₹250 crore deployed in business, primarily capex2.5 years
Capex for two additional CDMO customers₹50–75 crore, revenue ₹150 crore+If agreements signed
Clarithromycin dry suspension launchLaunch"In this year"
Esomeprazole launch (Viatris, Arrotex)LaunchFY28
Medium-term growth20–25% CAGR with EBITDA margins above 18%Beyond FY27

Key Metrics

MetricQ1 FY27
Operating income₹186.08 cr, up 21.16% YoY from ₹153.58 cr
Operating EBITDA₹33.32 cr, up 2.85x YoY from ₹8.66 cr
Operating EBITDA margin17.91%, up 1258 bps YoY from 5.33%
PAT excluding exceptional item₹24.68 cr, up 2.04x YoY from ₹8.12 cr
PAT margin13.26%, up 827 bps YoY from 4.99%
Export own-brands share of sales57.20%, up from 48% in Q1 FY26
Export contract manufacturing share of sales26.64%, down from 29% in Q1 FY26
Domestic branded generics share of sales6.41%, down from 10% in Q1 FY26
Domestic ethical division share of sales6.14%, down from 7% in Q1 FY26
Domestic contract manufacturing share of sales3.61%, down from 6% in Q1 FY26
Export gross margin~55%
Viatris CDMO sales in Q1₹5–6 cr from Ibuprofen and Clarithromycin granules
Ezetimibe + Atorvastatin Q1 sales~₹25 cr
FY27 expected export sales₹750 cr, with ~45% from CDMO
FY27 expected revenue₹900 cr
FY29 revenue guidance₹1,200 cr
FY30 revenue target₹1,500 cr minimum, net profit ₹200 cr plus
Total dossiers filed2,100+, up from 1,915+
Global product registrations850+, up from 750+
Dossier target by Q4 FY272,500
Capacity utilisation in Q1~70% for Ibuprofen and granules
Planned capex over 2–2.5 years₹250 cr, split across warehouse, capacity enhancement, and Jammu division
Synthimed budgeted EBITDA for FY27~₹750-odd cr